Displaying drugs 826 - 850 of 1588 in total
Omalizumab
Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reactions. By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its...
Approved
Investigational
Matched Description: … Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin …
Montelukast
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or...
Approved
Gallium citrate Ga-67
Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy...
Approved
Matched Description: … mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein …
Pegvisomant
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Approved
Tocopherol
Tocopherol exists in four different forms designated as α, β, δ, and γ. They present strong antioxidant activities, and it is determined as the major form of vitamin E. Tocopherol, as a group, is composed of soluble phenolic compounds that consist of a chromanol ring and a 16-carbon phytyl chain....
Approved
Investigational
Minocycline
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval...
Approved
Investigational
Paritaprevir
Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Investigational
Matched Description: … 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic ... viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein …
Colistin
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …
Thiotepa
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Mitoxantrone
An anthracenedione-derived antineoplastic agent.
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index …
Tioguanine
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Approved
Matched Categories: … Narrow Therapeutic Index Drugs …
Deoxycholic acid
Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve...
Approved
Matched Categories: … Other Miscellaneous Therapeutic Agents …
Capivasertib
Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. Therefore, significant research...
Approved
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Futibatinib
Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed...
Approved
Investigational
Matched Description: … FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated …
Matched Categories: … Protein Kinase Inhibitors …
Matched Categories: … Protein Kinase Inhibitors …
Deucravacitinib
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic …
Matched Categories: … Protein Kinase Inhibitors …
Matched Categories: … Protein Kinase Inhibitors …
Roxithromycin
Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is...
Approved
Investigational
Withdrawn
Matched Description: … exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein …
Eliglustat
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to...
Approved
Investigational
Matched Categories: … Other Miscellaneous Therapeutic Agents …
Levothyroxine
Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the...
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... UGT1A1 Substrates with a Narrow Therapeutic Index …
Tizanidine
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index …
Cytarabine
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale,...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Rucaparib
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Insulin pork
Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.
Approved
Erythromycin
Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those...
Approved
Investigational
Vet approved
Matched Categories: … Protein Synthesis Inhibitors …
Natalizumab
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the...
Approved
Investigational
Matched Description: … Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. …
Displaying drugs 826 - 850 of 1588 in total